Kenvue /$KVUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kenvue
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
Ticker
$KVUE
Sector
Primary listing
NYSE
Employees
22,000
Headquarters
Website
Kenvue Metrics
BasicAdvanced
$31B
21.92
$0.74
0.78
$0.82
5.12%
Price and volume
Market cap
$31B
Beta
0.78
52-week high
$25.17
52-week low
$15.47
Average daily volume
36M
Dividend rate
$0.82
Financial strength
Current ratio
0.978
Quick ratio
0.568
Long term debt to equity
66.664
Total debt to equity
81.491
Dividend payout ratio (TTM)
110.79%
Interest coverage (TTM)
6.00%
Profitability
EBITDA (TTM)
3,357
Gross margin (TTM)
58.15%
Net profit margin (TTM)
9.37%
Operating margin (TTM)
19.40%
Effective tax rate (TTM)
27.98%
Revenue per employee (TTM)
$690,000
Management effectiveness
Return on assets (TTM)
6.85%
Return on equity (TTM)
13.56%
Valuation
Price to earnings (TTM)
21.916
Price to revenue (TTM)
2.053
Price to book
2.9
Price to tangible book (TTM)
-4.12
Price to free cash flow (TTM)
19.101
Free cash flow yield (TTM)
5.24%
Free cash flow per share (TTM)
0.849
Dividend yield (TTM)
5.07%
Forward dividend yield
5.12%
Growth
Revenue change (TTM)
-2.16%
Earnings per share change (TTM)
28.77%
What the Analysts think about Kenvue
Analyst ratings (Buy, Hold, Sell) for Kenvue stock.
Bulls say / Bears say
Kenvue beat expectations in first-quarter 2025 results, with adjusted EPS of $0.24 exceeding the $0.23 forecast and net sales of $3.74 billion surpassing the $3.68 billion estimate, fueled by strong self-care segment revenue of $1.67 billion (Reuters).
In Q2 2025, Kenvue reported adjusted profit of $0.29 per share, ahead of the Street’s $0.28 consensus, showing profit durability during its strategic review (Reuters).
Activist investor Sachem Head acquired a 10.6 million-share position as of June 30, 2025—making it Kenvue’s fourth-largest shareholder—signaling investor belief in the company's plans to unlock value (Reuters).
Sales declined 4% in both Q1 and Q2 2025, highlighting ongoing revenue challenges across Kenvue's product range (FT).
The skin-health and beauty division lagged in Q1 2025, with sales dropping 7.3% to $977 million, below analyst expectations of $1.09 billion (Reuters).
Since its May 2023 spin-off, Kenvue's share price has dropped nearly 20%, trailing competitors like Colgate-Palmolive and Johnson & Johnson (FT).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
Kenvue Financial Performance
Revenues and expenses
Kenvue Earnings Performance
Company profitability
Kenvue News
AllArticlesVideos
Does Tylenol cause autism? Researchers can use ‘natural experiments' to study the link, write Drs.
WSJ5 days ago
These U.S. politicians dumped Tylenol maker shares before Trump's autism warning
Finbold2 weeks ago
The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.
WSJ2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kenvue stock?
Kenvue (KVUE) has a market cap of $31B as of October 08, 2025.
What is the P/E ratio for Kenvue stock?
The price to earnings (P/E) ratio for Kenvue (KVUE) stock is 21.92 as of October 08, 2025.
Does Kenvue stock pay dividends?
Yes, the Kenvue (KVUE) stock pays dividends to shareholders. As of October 08, 2025, the dividend rate is $0.8225 and the yield is 5.12%. Kenvue has a payout ratio of 110.79% on a trailing twelve-month basis.
When is the next Kenvue dividend payment date?
The next Kenvue (KVUE) dividend payment date is unconfirmed.
What is the beta indicator for Kenvue ?
Kenvue (KVUE) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.